Management Board Started Building Approval Process of EMA Premises in Amsterdam
The European Medicines Agency’s (EMA) Management Board met yesterday in an extraordinary session to discuss EMA’s future premises in Amsterdam. EMA will move from London to Amsterdam before the end of March 2019, when the United Kingdom withdraws from the European Union (EU). The Dutch authorities have committed to building completely new, tailor-made premises for EMA in the business district Zuidas. The building will not be completed by 30 March 2019, when EMA has to be fully operational in Amsterdam. Therefore, the selection and availability of a temporary building was part of the Netherland’s bid to host the Agency. The Board was updated on the good progress made regarding EMA’s temporary premises, which are located in the Sloterdijk area of Amsterdam. A delegation from the Netherlands confirmed that the Spark building will be refurbished by the Dutch authorities in line with EMA’s requirements and will be made available on 1 January 2019. This will allow EMA to gradually move all staff to Amsterdam before the end of March 2019. The interim solution ensures EMA’s business continuity in Amsterdam for the limited time until its new permanent building is completed on 15 November 2019. The representatives from the Dutch government also presented details on EMA’s permanent building in the Zuidas district. The Board was pleased to hear that the Netherlands are committed to ensuring a seamless transition of the Agency’s operations in the course of the relocation to Amsterdam and that the permanent building is expected to meet EMA’s long-term requirements. As a first step in the building approval process, the Board discussed key elements of the dossier to be submitted to the Budgetary Authority (comprising the European Council and Parliament) and asked for additional information in order to progress the notification procedure in the shortest possible timeframe. The notification of EMA’s intention to move to the permanent building is required by the Agency’s financial regulation and is a building block of the approval process. EMA can only enter into a contractual obligation for its new final premises on the basis of a positive opinion from the Budgetary Authority.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
